Show simple item record

dc.contributor.author Kovács, Tibor
dc.date.accessioned 2015-02-04T11:40:56Z
dc.date.available 2015-02-04T11:40:56Z
dc.date.issued 2014
dc.identifier.citation pagination=1655-1660; journalVolume=155; journalIssueNumber=42; journalTitle=ORVOSI HETILAP;
dc.identifier.uri http://repo.lib.semmelweis.hu//handle/123456789/1258
dc.identifier.uri doi:10.1556/OH.2014.30021
dc.description.abstract Non-valvular atrial fibrillation is one of the most important risk factor for embolic cerebral infarcts. Besides vitamin K antagonists, recently developed novel oral anticoagulants are gaining an increasing role in its treatment. Dabigatran, rivaroxaban and apixaban are novel oral anticoagulants available in the routine clinical practice. This review summarizes their use and the corresponding guidelines in the secondary prevention of ischemic stroke, by answering questions raised in relation of a hypothetical case report.
dc.relation.ispartof urn:issn:0030-6002
dc.title Stroke-prevenció stroke után pitvarfibrillacióban - eseten alapuló áttekintés.
dc.type Journal Article
dc.date.updated 2015-01-27T11:45:54Z
dc.language.rfc3066 hu
dc.identifier.mtmt 2794840
dc.identifier.pubmed 25305723
dc.contributor.department SE/AOK/K/Neurológiai Klinika
dc.contributor.institution Semmelweis Egyetem


Files in this item

xmlui.dri2xhtml.METS-1.0.onlyFromAllowedIP

View/Open

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account